Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
For individuals struggling with both obesity and cardiovascular disease, semaglutide offers a promising option to address these interrelated health concerns simultaneously
No diagnosis
Second-, third- and fourth-line treatments for this population include phentermine/topiramate (Qsymia, Vivus), liraglutide (Victoza/Saxenda, Novo Nordisk) and naltrexone/bupropion (Contrave, Currax Pharmaceuticals), respectively
Moreover, GIP also enhances insulin secretion in a glucose-dependent manner and improves fat metabolism by promoting lipogenesis and adipocyte insulin sensitivity
Rapid weight loss can lead to various side effects, like fatigue, gastrointestinal problems, hair loss, changes in facial appearance, visible signs of premature aging, digestive issues, reduced muscle mass and bone density, and mental health issues such as depression and anxiety
US$ 20.88
US$ 23.37
US$ 24.65
US$ 22.66
US$ 29.00
